We recently demonstrated that targeting E26 transformation–specific (ETS) variant transcription factor 2, an ETS family transcription factor specifically in TSC2-deficient cell promotes cytocidal response via regulation of poly(ADP-ribose) polymerase (PARP)-1 binding protein and therefore can have therapeutic potential in LAM or other TSC manifestations (19). This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.